BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, Alvarez Gil A, Poggioli R, Ruiz P, Marttos AC, Hirani K, Bell CA, Kusack H, Rafkin L, Baidal D, Pastewski A, Gawri K, Leñero C, Mantero AMA, Metalonis SW, Wang X, Roque L, Masters B, Kenyon NS, Ginzburg E, Xu X, Tan J, Caplan AI, Glassberg MK, Alejandro R, Ricordi C. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med 2021;10:660-73. [PMID: 33400390 DOI: 10.1002/sctm.20-0472] [Cited by in Crossref: 26] [Cited by in F6Publishing: 48] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang Y, Li X, Yang L. Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment. Stem Cell Res Ther 2022;13:410. [PMID: 35962458 DOI: 10.1186/s13287-022-03034-4] [Reference Citation Analysis]
2 Liu C, Xiao K, Xie L. Advances in mesenchymal stromal cell therapy for acute lung injury/acute respiratory distress syndrome. Front Cell Dev Biol 2022;10:951764. [DOI: 10.3389/fcell.2022.951764] [Reference Citation Analysis]
3 Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, Nguyen GH, Le PTT, Hoang VT, Forsyth NR, Heke M, Nguyen LT. Stem cell-based therapy for human diseases. Signal Transduct Target Ther 2022;7:272. [PMID: 35933430 DOI: 10.1038/s41392-022-01134-4] [Reference Citation Analysis]
4 Chen CY, Chen WC, Hsu CK, Chao CM, Lai CC. The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. J Infect Public Health 2022;15:896-901. [PMID: 35849852 DOI: 10.1016/j.jiph.2022.07.001] [Reference Citation Analysis]
5 Weiss DJ, Filiano A, Galipeau J, Khoury M, Krampera M, Lalu M, Blanc KL, Nolta J, Phinney DG, Rocco PR, Shi Y, Tarte K, Viswanathan S, Martin I. An ISCT MSC Committee Editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for COVID-19: Time for a global registry. Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2022.07.010] [Reference Citation Analysis]
6 Aghayan HR, Salimian F, Abedini A, Fattah Ghazi S, Yunesian M, Alavi-Moghadam S, Makarem J, Majidzadeh-A K, Hatamkhani A, Moghri M, Danesh A, Haddad-Marandi MR, Sanati H, Abbasvandi F, Arjmand B, Azimi P, Ghavamzadeh A, Sarrami-Forooshani R. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment. Stem Cell Res Ther 2022;13:365. [PMID: 35902979 DOI: 10.1186/s13287-022-02953-6] [Reference Citation Analysis]
7 Tan MI, Alfarafisa NM, Septiani P, Barlian A, Firmansyah M, Faizal A, Melani L, Nugrahapraja H. Potential Cell-Based and Cell-Free Therapy for Patients with COVID-19. Cells 2022;11:2319. [DOI: 10.3390/cells11152319] [Reference Citation Analysis]
8 Shi L, Zheng Y, Cheng Z, Ji N, Niu C, Wang Y, Huang T, Li R, Huang M, Chen X, Shu L, Wu M, Deng K, Wei J, Wang X, Cao Y, Yan J, Feng G. One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment. Stem Cell Res Ther 2022;13:321. [PMID: 35842684 DOI: 10.1186/s13287-022-02972-3] [Reference Citation Analysis]
9 Chaudhary JK, Saini D, Chaudhary PK, Maurya A, Verma GK, Gupta AK, Roshan R, Vats TK, Garg N, Yadav D, Kant N, Meena AK, Mirza-shariff AA. Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19. Cells 2022;11:2175. [DOI: 10.3390/cells11142175] [Reference Citation Analysis]
10 Schultz IC, Bertoni APS, Wink MR. MSC-Exosomes Carrying miRNA - Could they Enhance Tocilizumab Activity in Neuropathology of COVID-19? Stem Cell Rev Rep 2022. [PMID: 35794511 DOI: 10.1007/s12015-022-10409-w] [Reference Citation Analysis]
11 Rossello-Gelabert M, Gonzalez-Pujana A, Igartua M, Santos-Vizcaino E, Hernandez RM. Clinical progress in MSC-based therapies for the management of severe COVID-19. Cytokine Growth Factor Rev 2022:S1359-6101(22)00050-8. [PMID: 35843774 DOI: 10.1016/j.cytogfr.2022.07.002] [Reference Citation Analysis]
12 Grégoire C, Layios N, Lambermont B, Lechanteur C, Briquet A, Bettonville V, Baudoux E, Thys M, Dardenne N, Misset B, Beguin Y. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Front Immunol 2022;13:932360. [DOI: 10.3389/fimmu.2022.932360] [Reference Citation Analysis]
13 Boland L, Bitterlich LM, Hogan AE, Ankrum JA, English K. Translating MSC Therapy in the Age of Obesity. Front Immunol 2022;13:943333. [DOI: 10.3389/fimmu.2022.943333] [Reference Citation Analysis]
14 Li YE, Ajoolabady A, Dhanasekaran M, Ren J. Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy. Pharmacol Res 2022;182:106334. [PMID: 35779816 DOI: 10.1016/j.phrs.2022.106334] [Reference Citation Analysis]
15 Kirkham AM, Bailey AJM, Monaghan M, Shorr R, Lalu MM, Fergusson DA, Allan DS. Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval. Stem Cells Transl Med 2022:szac038. [PMID: 35758400 DOI: 10.1093/stcltm/szac038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Cuevas-González MV, Cuevas-González JC. Stem cells as an option for the treatment of COVID-19. World J Clin Cases 2022; 10(18): 6338-6340 [DOI: 10.12998/wjcc.v10.i18.6338] [Reference Citation Analysis]
17 Wang J, Luo F, Suo Y, Zheng Y, Chen K, You D, Liu Y. Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: a systematic review and meta-analysis based on phase I and II RCTs. Stem Cell Res Ther 2022;13:275. [PMID: 35752865 DOI: 10.1186/s13287-022-02956-3] [Reference Citation Analysis]
18 Zhang M, Yan X, Shi M, Li R, Pi Z, Ren X, Wang Y, Yan S, Wang Y, Jin Y, Wang X. Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis. Glob Health Res Policy 2022;7:19. [PMID: 35733229 DOI: 10.1186/s41256-022-00251-5] [Reference Citation Analysis]
19 Javed A, Karki S, Sami Z, Khan Z, Shree A, Sah BK, Ghosh S, Saxena S, Chen H. Association between Mesenchymal Stem Cells and COVID-19 Therapy: Systematic Review and Current Trends. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/9346939] [Reference Citation Analysis]
20 Huang A, Liu Y, Qi X, Chen S, Huang H, Zhang J, Han Z, Han ZC, Li Z. Intravenously transplanted mesenchymal stromal cells: a new endocrine reservoir for cardioprotection. Stem Cell Res Ther 2022;13:253. [PMID: 35715868 DOI: 10.1186/s13287-022-02922-z] [Reference Citation Analysis]
21 Taylor SD, Serpa PBS, Santos AP, Hart KA, Vaughn SA, Moore GE, Mukhopadhyay A, Page AE. Effects of intravenous administration of peripheral blood-derived mesenchymal stromal cells after infusion of lipopolysaccharide in horses. J Vet Intern Med 2022. [PMID: 35698909 DOI: 10.1111/jvim.16447] [Reference Citation Analysis]
22 Zhu YG, Shi MM, Monsel A, Dai CX, Dong X, Shen H, Li SK, Chang J, Xu CL, Li P, Wang J, Shen MP, Ren CJ, Chen DC, Qu JM. Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study. Stem Cell Res Ther 2022;13:220. [PMID: 35619189 DOI: 10.1186/s13287-022-02900-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, McGuigan P, Jackson C, Boyle R, McFerran J, McDowell C, Campbell C, McFarland M, Smythe J, Thompson J, Williams B, Curley G, Laffey JG, Clarke M, McAuley DF, O'Kane C. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial. Trials 2022;23:401. [PMID: 35562778 DOI: 10.1186/s13063-022-06220-0] [Reference Citation Analysis]
24 Jones OY, Mccurdy D. Cell Based Treatment of Autoimmune Diseases in Children. Front Pediatr 2022;10:855260. [DOI: 10.3389/fped.2022.855260] [Reference Citation Analysis]
25 Zhang W, Qin C, Fei Y, Shen M, Zhou Y, Zhang Y, Zeng X, Zhang S. Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update. Clin Immunol 2022;:109022. [PMID: 35477027 DOI: 10.1016/j.clim.2022.109022] [Reference Citation Analysis]
26 Mönch D, Reinders MEJ, Dahlke MH, Hoogduijn MJ. How to Make Sense out of 75,000 Mesenchymal Stromal Cell Publications? Cells 2022;11:1419. [DOI: 10.3390/cells11091419] [Reference Citation Analysis]
27 Wiese DM, Wood CA, Braid LR. From Vial to Vein: Crucial Gaps in Mesenchymal Stromal Cell Clinical Trial Reporting. Front Cell Dev Biol 2022;10:867426. [DOI: 10.3389/fcell.2022.867426] [Reference Citation Analysis]
28 Wang C, Zhao D, Zheng L, Bao X, Yang Q, Jiang S, Zhou X, Tang L, Liu Z. Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial. BMJ Open 2022;12:e058444. [PMID: 35379638 DOI: 10.1136/bmjopen-2021-058444] [Reference Citation Analysis]
29 Farhangnia P, Dehrouyeh S, Safdarian AR, Farahani SV, Gorgani M, Rezaei N, Akbarpour M, Delbandi A. Recent Advances in Passive Immunotherapies for COVID-19: The Evidence-Based Approaches and Clinical Trials. International Immunopharmacology 2022. [DOI: 10.1016/j.intimp.2022.108786] [Reference Citation Analysis]
30 Karyana M, Djaharuddin I, Rif'ati L, Arif M, Choi MK, Angginy N, Yoon A, Han J, Josh F, Arlinda D, Narulita A, Muchtar F, Bakri RA, Irmansyah S. Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial. Stem Cell Res Ther 2022;13:134. [PMID: 35365239 DOI: 10.1186/s13287-022-02812-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Jovic D, Yu Y, Wang D, Wang K, Li H, Xu F, Liu C, Liu J, Luo Y. A Brief Overview of Global Trends in MSC-Based Cell Therapy. Stem Cell Rev Rep 2022. [PMID: 35344199 DOI: 10.1007/s12015-022-10369-1] [Reference Citation Analysis]
32 Yao W, Shi L, Zhang Y, Dong H, Zhang Y. Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives. Stem Cell Res Ther 2022;13:124. [PMID: 35321737 DOI: 10.1186/s13287-022-02810-6] [Reference Citation Analysis]
33 Shahrbaf MA, Nouri M, Zarrabi M, Gramignoli R, Vosough M. Extraembryonic Mesenchymal Stromal/Stem Cells in Liver Diseases: A Critical Revision of Promising Advanced Therapy Medicinal Products. Cells 2022;11:1074. [PMID: 35406638 DOI: 10.3390/cells11071074] [Reference Citation Analysis]
34 Rebelatto CLK, Senegaglia AC, Franck CL, Daga DR, Shigunov P, Stimamiglio MA, Marsaro DB, Schaidt B, Micosky A, de Azambuja AP, Leitão CA, Petterle RR, Jamur VR, Vaz IM, Mallmann AP, Carraro Junior H, Ditzel E, Brofman PRS, Correa A. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Res Ther 2022;13:122. [PMID: 35313959 DOI: 10.1186/s13287-022-02796-1] [Reference Citation Analysis]
35 Xu R, Feng Z, Wang FS. Mesenchymal stem cell treatment for COVID-19. EBioMedicine 2022;77:103920. [PMID: 35279630 DOI: 10.1016/j.ebiom.2022.103920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Krawczenko A, Klimczak A. Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells and Their Contribution to Angiogenic Processes in Tissue Regeneration. Int J Mol Sci 2022;23:2425. [PMID: 35269568 DOI: 10.3390/ijms23052425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Monsel A, Hauw-berlemont C, Mebarki M, Heming N, Mayaux J, Nguekap Tchoumba O, Diehl J, Demoule A, Annane D, Marois C, Demeret S, Weiss E, Voiriot G, Fartoukh M, Constantin J, Mégarbane B, Plantefève G, Malard-castagnet S, Burrel S, Rosenzwajg M, Tchitchek N, Boucher-pillet H, Churlaud G, Cras A, Maheux C, Pezzana C, Diallo MH, Ropers J, Menasché P, Larghero J, Benchetrit D, Bonvallot H, Charbonnier-beaupel F, Dhib-charfi M, Delmotte PR, Kone A, Le Corre M, Marcelin A, Metz C, Puybasset L, Salem J, Vezinet C; APHP STROMA–CoV-2 Collaborative Research Group. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit Care 2022;26. [DOI: 10.1186/s13054-022-03930-4] [Reference Citation Analysis]
38 Chen L, Qu J, Kalyani FS, Zhang Q, Fan L, Fang Y, Li Y, Xiang C. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-021-04096-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Kebria MM, Milan PB, Peyravian N, Kiani J, Khatibi S, Mozafari M. Stem cell therapy for COVID-19 pneumonia. Mol Biomed 2022;3:6. [PMID: 35174448 DOI: 10.1186/s43556-021-00067-8] [Reference Citation Analysis]
40 Miguez-Rey E, Choi D, Kim S, Yoon S, Săndulescu O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opin Investig Drugs 2022;:1-18. [PMID: 35164631 DOI: 10.1080/13543784.2022.2030310] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
41 Lu K, Geng ST, Tang S, Yang H, Xiong W, Xu F, Yuan Q, Xiao X, Huang R, Liang H, Chen Z, Qian C, Li Y, Wang S. Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19. Stem Cell Res Ther 2022;13:61. [PMID: 35130977 DOI: 10.1186/s13287-022-02743-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Zhao F, Ma Q, Yue Q, Chen H. SARS-CoV-2 Infection and Lung Regeneration. Clin Microbiol Rev 2022;:e0018821. [PMID: 35107300 DOI: 10.1128/cmr.00188-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Karakaş N, Üçüncüoğlu S, Uludağ D, Karaoğlan BS, Shah K, Öztürk G. Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells 2022;11:465. [DOI: 10.3390/cells11030465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Gupta N. Protease Activated Receptors: A Pathway to Boosting Mesenchymal Stromal Cell Therapeutic Efficacy in Acute Respiratory Distress Syndrome? Int J Mol Sci 2022;23:1277. [PMID: 35163205 DOI: 10.3390/ijms23031277] [Reference Citation Analysis]
45 Vaka R, Khan S, Ye B, Risha Y, Parent S, Courtman D, Stewart DJ, Davis DR. Direct comparison of different therapeutic cell types susceptibility to inflammatory cytokines associated with COVID-19 acute lung injury. Stem Cell Res Ther 2022;13:20. [PMID: 35033181 DOI: 10.1186/s13287-021-02699-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Niknam Z, Jafari A, Golchin A, Danesh Pouya F, Nemati M, Rezaei-Tavirani M, Rasmi Y. Potential therapeutic options for COVID-19: an update on current evidence. Eur J Med Res 2022;27:6. [PMID: 35027080 DOI: 10.1186/s40001-021-00626-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
47 Ikram R, Shamsuddin SAA, Mohamed Jan B, Abdul Qadir M, Kenanakis G, Stylianakis MM, Anastasiadis SH. Impact of Graphene Derivatives as Artificial Extracellular Matrices on Mesenchymal Stem Cells. Molecules 2022;27:379. [PMID: 35056690 DOI: 10.3390/molecules27020379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
48 Kirkham AM, Monaghan M, Bailey AJ, Shorr R, Lalu MM, Fergusson DA, Allan DS. Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis. Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2021.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
49 Chen T, Zhang S, Jin H, Fu X, Shang L, Lu Y, Sun Y, Hisham Yahaya B, Liu Y, Lin J. Nonfreezing Low Temperature Maintains the Viability of Menstrual Blood-Derived Endometrial Stem Cells Under Oxygen-Glucose Deprivation Through the Sustained Release of Autophagy-Produced Energy. Cell Transplant 2022;31:9636897221086971. [PMID: 35416078 DOI: 10.1177/09636897221086971] [Reference Citation Analysis]
50 Masterson CH, Ceccato A, Artigas A, Dos Santos C, Rocco PR, Rolandsson Enes S, Weiss DJ, McAuley D, Matthay MA, English K, Curley GF, Laffey JG. Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges. Intensive Care Med Exp 2021;9:61. [PMID: 34970706 DOI: 10.1186/s40635-021-00424-5] [Reference Citation Analysis]
51 Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, Song J, Huang L, Xu Z, Fu JL, Li Y, Xu R, Li TT, Dong J, Cai J, Li G, Xie Y, Shi M, Li Y, Zhang Y, Xie WF, Wang FS. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine 2021;75:103789. [PMID: 34963099 DOI: 10.1016/j.ebiom.2021.103789] [Reference Citation Analysis]
52 Arabpour E, Khoshdel S, Tabatabaie N, Akhgarzad A, Zangiabadian M, Nasiri MJ. Stem Cells Therapy for COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:737590. [PMID: 34912818 DOI: 10.3389/fmed.2021.737590] [Reference Citation Analysis]
53 Hamzagic AR, Miloradovic D, Miloradovic D, Ivosevic Z, Ljujic B. Mesenchymal Stem Cells Versus Covid-19. Can They Win the Battle? Serbian Journal of Experimental and Clinical Research 2021;0. [DOI: 10.2478/sjecr-2021-0024] [Reference Citation Analysis]
54 da Silva KN, Pinheiro PCG, Gobatto ALN, Passos RDH, Paredes BD, França LSA, Nonaka CKV, Barreto-Duarte B, Araújo-Pereira M, Tibúrcio R, Cruz FF, Martins GLS, Andrade BB, de Castro-Faria-Neto HC, Rocco PRM, Souza BSF. Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report. Front Med (Lausanne) 2021;8:767291. [PMID: 34869480 DOI: 10.3389/fmed.2021.767291] [Reference Citation Analysis]
55 Aslan A, Aslan C, Zolbanin NM, Jafari R. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia (Nathan) 2021;13:14. [PMID: 34872623 DOI: 10.1186/s41479-021-00092-9] [Reference Citation Analysis]
56 Generali M, Kehl D, Wanner D, Okoniewski MJ, Hoerstrup SP, Cinelli P. Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells. J Cell Mol Med 2021. [PMID: 34821008 DOI: 10.1111/jcmm.17048] [Reference Citation Analysis]
57 Camelo S, Latil M, Agus S, Dioh W, Veillet S, Lafont R, Dilda PJ. A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality. Emerg Microbes Infect 2021;10:2256-63. [PMID: 34783636 DOI: 10.1080/22221751.2021.2006579] [Reference Citation Analysis]
58 Sun D, Jiang Z, Chen Y, Shang D, Miao P, Gao J. MiR-455-5p upregulation in umbilical cord mesenchymal stem cells attenuates endometrial injury and promotes repair of damaged endometrium via Janus kinase/signal transducer and activator of transcription 3 signaling. Bioengineered 2021. [PMID: 34784837 DOI: 10.1080/21655979.2021.2006976] [Reference Citation Analysis]
59 Šikić J, Planinić Z, Matišić V, Friščić T, Molnar V, Jagačić D, Vujičić L, Tudorić N, Postružin Gršić L, Ljubičić Đ, Primorac D. COVID-19: The Impact on Cardiovascular System. Biomedicines 2021;9:1691. [PMID: 34829920 DOI: 10.3390/biomedicines9111691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ventura-Carmenate Y, Alkaabi FM, Castillo-Aleman YM, Villegas-Valverde CA, Ahmed YM, Sanna P, Almarzooqi AA, Abdelrazik A, Torres-Zambrano GM, Wade-Mateo M, Quesada-Saliba D, Abdel Hadi L, Bencomo-Hernandez AA, Rivero-Jimenez RA. Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020. Transl Med Commun 2021;6:25. [PMID: 34746417 DOI: 10.1186/s41231-021-00101-5] [Reference Citation Analysis]
61 Turner L, Munsie M, Levine AD, Ikonomou L. Ethical issues and public communication in the development of cell-based treatments for COVID-19: Lessons from the pandemic. Stem Cell Reports 2021;16:2567-76. [PMID: 34653406 DOI: 10.1016/j.stemcr.2021.09.005] [Reference Citation Analysis]
62 Zanirati G, Provenzi L, Libermann LL, Bizotto SC, Ghilardi IM, Marinowic DR, Shetty AK, Da Costa JC. Stem cell-based therapy for COVID-19 and ARDS: a systematic review. NPJ Regen Med 2021;6:73. [PMID: 34750382 DOI: 10.1038/s41536-021-00181-9] [Reference Citation Analysis]
63 Dunbar H, Weiss DJ, Rolandsson Enes S, Laffey JG, English K. The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing. Cells 2021;10:2982. [PMID: 34831203 DOI: 10.3390/cells10112982] [Reference Citation Analysis]
64 Li C, Zhao H, Cheng L, Wang B. Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice. Cell Biosci 2021;11:187. [PMID: 34727974 DOI: 10.1186/s13578-021-00698-y] [Reference Citation Analysis]
65 Sanie-Jahromi F, NejatyJahromy Y, Jahromi RR. A Review on the Role of Stem Cells against SARS-CoV-2 in Children and Pregnant Women. Int J Mol Sci 2021;22:11787. [PMID: 34769218 DOI: 10.3390/ijms222111787] [Reference Citation Analysis]
66 Sanberg P, Morrison DC, Kovacs RA, Bjugstad K. A Retrospective Look at Recent COVID-19 Articles Published in Cell Transplantation: Research Leading to Further Understanding. Cell Transplant 2021;30:9636897211049814. [PMID: 34689578 DOI: 10.1177/09636897211049814] [Reference Citation Analysis]
67 Bhalerao A, Raut S, Noorani B, Mancuso S, Cucullo L. Molecular Mechanisms of Multi-Organ Failure in COVID-19 and Potential of Stem Cell Therapy. Cells 2021;10:2878. [PMID: 34831101 DOI: 10.3390/cells10112878] [Reference Citation Analysis]
68 Fang J, Feng C, Chen W, Hou P, Liu Z, Zuo M, Han Y, Xu C, Melino G, Verkhratsky A, Wang Y, Shao C, Shi Y. Redressing the interactions between stem cells and immune system in tissue regeneration. Biol Direct 2021;16:18. [PMID: 34670590 DOI: 10.1186/s13062-021-00306-6] [Reference Citation Analysis]
69 Xu Z, Huang Y, Zhou J, Deng X, He W, Liu X, Li Y, Zhong N, Sang L. Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS. Front Immunol 2021;12:738697. [PMID: 34659231 DOI: 10.3389/fimmu.2021.738697] [Reference Citation Analysis]
70 Infante A, Rodríguez CI. Cell and Cell-Free Therapies to Counteract Human Premature and Physiological Aging: MSCs Come to Light. J Pers Med 2021;11:1043. [PMID: 34683184 DOI: 10.3390/jpm11101043] [Reference Citation Analysis]
71 Zhang C, Jin H, Wen YF, Yin G. Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Front Public Health 2021;9:729559. [PMID: 34650951 DOI: 10.3389/fpubh.2021.729559] [Reference Citation Analysis]
72 Sadeghi B, Roshandel E, Pirsalehi A, Kazemi S, Sankanian G, Majidi M, Salimi M, Aghdami N, Sadrosadat H, Samadi Kochaksaraei S, Alaeddini F, Ringden O, Hajifathali A. Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells. J Cell Mol Med 2021;25:10554-64. [PMID: 34632708 DOI: 10.1111/jcmm.16986] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Ghaffari S, Kazerooni H, Salehi-Najafabadi A. An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19. Int Immunopharmacol 2021;101:108226. [PMID: 34634685 DOI: 10.1016/j.intimp.2021.108226] [Reference Citation Analysis]
74 Ligotti ME, Pojero F, Accardi G, Aiello A, Caruso C, Duro G, Candore G. Immunopathology and Immunosenescence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation? Front Cell Dev Biol 2021;9:725606. [PMID: 34595175 DOI: 10.3389/fcell.2021.725606] [Reference Citation Analysis]
75 Wang J, Shi P, Chen D, Wang S, Wang P, Feng X, Zhang L. Research Status of the Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of COVID-19-Related Pneumonia: A Systematic Review and Meta-Analysis. Stem Cells Dev 2021;30:947-69. [PMID: 34416823 DOI: 10.1089/scd.2021.0179] [Reference Citation Analysis]
76 Patel PM, Connolly MR, Coe TM, Calhoun A, Pollok F, Markmann JF, Burdorf L, Azimzadeh A, Madsen JC, Pierson RN 3rd. Minimizing Ischemia Reperfusion Injury in Xenotransplantation. Front Immunol 2021;12:681504. [PMID: 34566955 DOI: 10.3389/fimmu.2021.681504] [Reference Citation Analysis]
77 Abu-El-Rub E, Khasawneh RR, Almahasneh F, Altaany Z, Bataineh N, Zegallai H, Sekaran S. Mesenchymal stem cells and COVID-19: What they do and what they can do. World J Stem Cells 2021; 13(9): 1318-1337 [PMID: 34630865 DOI: 10.4252/wjsc.v13.i9.1318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, Izcovich A, Mangala S, Ge L, Han MA, Agoritsas T, Arnold D, Ávila C, Chu DK, Couban R, Cusano E, Darzi AJ, Devji T, Foroutan F, Ghadimi M, Khamis A, Lamontagne F, Loeb M, Miroshnychenko A, Motaghi S, Murthy S, Mustafa RA, Rada G, Rochwerg B, Switzer C, Vandvik PO, Vernooij RW, Wang Y, Yao L, Guyatt GH, Brignardello-Petersen R. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ 2021;374:n2231. [PMID: 34556486 DOI: 10.1136/bmj.n2231] [Reference Citation Analysis]
79 Cenko E, Badimon L, Bugiardini R, Claeys MJ, De Luca G, de Wit C, Derumeaux G, Dorobantu M, Duncker DJ, Eringa EC, Gorog DA, Hassager C, Heinzel FR, Huber K, Manfrini O, Milicic D, Oikonomou E, Padro T, Trifunovic-Zamaklar D, Vasiljevic-Pokrajcic Z, Vavlukis M, Vilahur G, Tousoulis D. Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). Cardiovasc Res 2021:cvab298. [PMID: 34528075 DOI: 10.1093/cvr/cvab298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Takao S, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Takahashi S, Nakashima A, Hattori N. Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther 2021;12:506. [PMID: 34530920 DOI: 10.1186/s13287-021-02574-5] [Reference Citation Analysis]
81 Primorac D, Čemerin M, Matišić V, Molnar V, Strbad M, Girandon L, Zenić L, Knežević M, Minger S, Polančec D. Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment. Pharmaceutics 2021;13:1481. [PMID: 34575557 DOI: 10.3390/pharmaceutics13091481] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Shetty AK, Shetty PA, Zanirati G, Jin K. Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS. NPJ Regen Med 2021;6:53. [PMID: 34504110 DOI: 10.1038/s41536-021-00161-z] [Reference Citation Analysis]
83 Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, Li T, Hu W, Zhen C, Wang FS. Mesenchymal stem cell therapy for severe COVID-19. Signal Transduct Target Ther 2021;6:339. [PMID: 34497264 DOI: 10.1038/s41392-021-00754-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Alanazi A. COVID-19 and the role of stem cells. Regen Ther 2021;18:334-8. [PMID: 34462723 DOI: 10.1016/j.reth.2021.08.008] [Reference Citation Analysis]
85 Zhao Y, Yan Z, Liu Y, Zhang Y, Shi J, Li J, Ji F. Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application. Stem Cell Res Ther 2021;12:470. [PMID: 34420515 DOI: 10.1186/s13287-021-02551-y] [Reference Citation Analysis]
86 Abdelgawad M, Bakry NS, Farghali AA, Abdel-Latif A, Lotfy A. Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects. Stem Cell Res Ther 2021;12:469. [PMID: 34419143 DOI: 10.1186/s13287-021-02542-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Zaki MM, Lesha E, Said K, Kiaee K, Robinson-McCarthy L, George H, Hanna A, Appleton E, Liu S, Ng AHM, Khoshakhlagh P, Church GM. Cell therapy strategies for COVID-19: Current approaches and potential applications. Sci Adv 2021;7:eabg5995. [PMID: 34380619 DOI: 10.1126/sciadv.abg5995] [Reference Citation Analysis]
88 Fears R, Akutsu H, Alentajan-Aleta LT, Caicedo A, Campos de Carvalho AC, Čolić M, Cornish J, Cossu G, Debré P, Dierckxsens G, El-Badri N, Griffin G, Chingo-Ho Hsieh P, Inamdar MS, Kumar P, Abraham CM, Maciulaitis R, Al Mahtab M, O'Brien FJ, Pepper MS, Meulen VT. Inclusivity and diversity: Integrating international perspectives on stem cell challenges and potential. Stem Cell Reports 2021;16:1847-52. [PMID: 34329597 DOI: 10.1016/j.stemcr.2021.07.003] [Reference Citation Analysis]
89 Ernzen K, Trask AJ, Peeples ME, Garg V, Zhao MT. Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Rev Rep 2021. [PMID: 34365591 DOI: 10.1007/s12015-021-10229-4] [Reference Citation Analysis]
90 Taechangam N, Kol A, Arzi B, Borjesson DL. Multipotent Stromal Cells and Viral Interaction: Current Implications for Therapy. Stem Cell Rev Rep 2021. [PMID: 34347271 DOI: 10.1007/s12015-021-10224-9] [Reference Citation Analysis]
91 Chen L, Qu J, Mei Q, Chen X, Fang Y, Chen L, Li Y, Xiang C. Small extracellular vesicles from menstrual blood-derived mesenchymal stem cells (MenSCs) as a novel therapeutic impetus in regenerative medicine. Stem Cell Res Ther 2021;12:433. [PMID: 34344458 DOI: 10.1186/s13287-021-02511-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Wang L, Li Y, Xu M, Deng Z, Zhao Y, Yang M, Liu Y, Yuan R, Sun Y, Zhang H, Wang H, Qian Z, Kang H. Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells. Front Immunol 2021;12:726909. [PMID: 34394132 DOI: 10.3389/fimmu.2021.726909] [Reference Citation Analysis]
93 da Silva KN, Gobatto ALN, Costa-Ferro ZSM, Cavalcante BRR, Caria ACI, de Aragão França LS, Nonaka CKV, de Macêdo Lima F, Lopes-Pacheco M, Rocco PRM, de Freitas Souza BS. Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19? Stem Cell Res Ther 2021;12:425. [PMID: 34315546 DOI: 10.1186/s13287-021-02502-7] [Reference Citation Analysis]
94 Saleh M, Vaezi AA, Aliannejad R, Sohrabpour AA, Kiaei SZF, Shadnoush M, Siavashi V, Aghaghazvini L, Khoundabi B, Abdoli S, Chahardouli B, Seyhoun I, Alijani N, Verdi J. Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial. Stem Cell Res Ther 2021;12:410. [PMID: 34271988 DOI: 10.1186/s13287-021-02483-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
95 Sharma D, Zhao F. Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19. NPJ Regen Med 2021;6:37. [PMID: 34193864 DOI: 10.1038/s41536-021-00147-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Feng G, Shi L, Huang T, Ji N, Zheng Y, Lin H, Niu C, Wang Y, Li R, Huang M, Chen X, Shu L, Wu M, Deng K, Wei J, Wang X, Cao Y, Yan J. Human Umbilical Cord Mesenchymal Stromal Cell Treatment of Severe COVID-19 Patients: A 3-Month Follow-Up Study Following Hospital Discharge. Stem Cells Dev 2021;30:773-81. [PMID: 34044609 DOI: 10.1089/scd.2021.0015] [Reference Citation Analysis]
97 Marrazzo P, Pizzuti V, Zia S, Sargenti A, Gazzola D, Roda B, Bonsi L, Alviano F. Microfluidic Tools for Enhanced Characterization of Therapeutic Stem Cells and Prediction of Their Potential Antimicrobial Secretome. Antibiotics (Basel) 2021;10:750. [PMID: 34206190 DOI: 10.3390/antibiotics10070750] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
98 Sharma S, Jeyaraman M, Muthu S, Anudeep TC, Jeyaraman N, Shringeri AS, Kumar V, Somasundaram R, Jain R, Jha SK. A Step Toward Optimizing Regenerative Medicine Principle to Combat COVID-19. Ann Natl Acad Med Sci 2021;57:202-13. [DOI: 10.1055/s-0041-1731597] [Reference Citation Analysis]
99 Senegaglia AC, Rebelatto CLK, Franck CL, Lima JS, Boldrini-Leite LM, Daga DR, Leitão CA, Shigunov P, de Azambuja AP, Bana E, Marsaro DB, Schaidt B, Micosky A, Jamur VR, Schluga Y, Vaz IM, Ribeiro LL, Correa A, Brofman EPRS. Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report. Cell Transplant 2021;30:9636897211021008. [PMID: 34074163 DOI: 10.1177/09636897211021008] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
100 Kim M, Knoepfler PS. Anticipated impact of stem cell and other cellular medicine clinical trials for COVID-19. Regen Med 2021;16:525-33. [PMID: 34114493 DOI: 10.2217/rme-2021-0025] [Reference Citation Analysis]
101 Inchingolo AD, Dipalma G, Inchingolo AM, Malcangi G, Santacroce L, D'Oria MT, Isacco CG, Bordea IR, Candrea S, Scarano A, Morandi B, Del Fabbro M, Farronato M, Tartaglia GM, Balzanelli MG, Ballini A, Nucci L, Lorusso F, Taschieri S, Inchingolo F. The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. Antioxidants (Basel) 2021;10:881. [PMID: 34072708 DOI: 10.3390/antiox10060881] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
102 Afarid M, Sanie-Jahromi F. Mesenchymal Stem Cells and COVID-19: Cure, Prevention, and Vaccination. Stem Cells Int 2021;2021:6666370. [PMID: 34035820 DOI: 10.1155/2021/6666370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Carvalho JL, Silva-Carvalho AE, Garcez EM, Saldanha-Araujo F. Commentary: Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment. Front Immunol 2021;12:682195. [PMID: 33995424 DOI: 10.3389/fimmu.2021.682195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Pethe P, Kale V. Placenta: A gold mine for translational research and regenerative medicine. Reprod Biol 2021;21:100508. [PMID: 33930790 DOI: 10.1016/j.repbio.2021.100508] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Singh N, Villoutreix BO. Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. Comput Struct Biotechnol J 2021;19:2537-48. [PMID: 33936562 DOI: 10.1016/j.csbj.2021.04.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Ngo BT, Marik P, Kory P, Shapiro L, Thomadsen R, Iglesias J, Ditmore S, Rendell M, Varon J, Dubé M, Nanda N, In G, Arkfeld D, Chaudhary P, Campese VM, Hanna DL, Sawcer DE, Ehresmann G, Peng D, Smogorewski M, Armstrong A, Dasgupta R, Sattler F, Brennan-Rieder D, Mussini C, Mitja O, Soriano V, Peschanski N, Hayem G, Confalonieri M, Piccirillo MC, Lobo-Ferreira A, Bello Rivero I, Turkia M, Vinjevoll EH, Griffin D, Hung IF. The time to offer treatments for COVID-19. Expert Opin Investig Drugs 2021;30:505-18. [PMID: 33721548 DOI: 10.1080/13543784.2021.1901883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
107 Hernandez JJ, Beaty DE, Fruhwirth LL, Lopes Chaves AP, Riordan NH. Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells. J Transl Med 2021;19:149. [PMID: 33853637 DOI: 10.1186/s12967-021-02813-6] [Reference Citation Analysis]
108 Atkinson SP. A preview of selected articles. Stem Cells Transl Med 2021;10:643-6. [PMID: 33852778 DOI: 10.1002/sctm.21-0103] [Reference Citation Analysis]
109 Liu D, Zhang T, Wang Y, Xia L. The Centrality of Obesity in the Course of Severe COVID-19. Front Endocrinol (Lausanne) 2021;12:620566. [PMID: 33776917 DOI: 10.3389/fendo.2021.620566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Mebarki M, Abadie C, Larghero J, Cras A. Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candidate for the development of advanced therapy medicinal products. Stem Cell Res Ther 2021;12:152. [PMID: 33637125 DOI: 10.1186/s13287-021-02222-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
111 Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, Alvarez Gil A, Poggioli R, Ruiz P, Marttos AC, Hirani K, Bell CA, Kusack H, Rafkin L, Baidal D, Pastewski A, Gawri K, Leñero C, Mantero AMA, Metalonis SW, Wang X, Roque L, Masters B, Kenyon NS, Ginzburg E, Xu X, Tan J, Caplan AI, Glassberg MK, Alejandro R, Ricordi C. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med 2021;10:660-73. [PMID: 33400390 DOI: 10.1002/sctm.20-0472] [Cited by in Crossref: 26] [Cited by in F6Publishing: 48] [Article Influence: 26.0] [Reference Citation Analysis]